+1 858-523-8231
Login | Register
menu
AA Blocks, Building Blocks, Catalysts, Inhibitors
Login | Register
1354690-24-6,MFCD30470232
Catalog No.:AA01EN2Q

1354690-24-6 | Leniolisib

Pack Size
Purity
Availability
Price(USD)
Quantity
  
1mg
98%
in stock  
$19.00   $14.00
- +
5mg
98%
in stock  
$47.00   $33.00
- +
25mg
98%
in stock  
$119.00   $83.00
- +
  • Technical Information
  • Properties
  • Downstream Synthesis Route
  • Literature
  • Request for Quotation
  • Download SDS
Technical Information
Catalog Number:
AA01EN2Q
Chemical Name:
Leniolisib
CAS Number:
1354690-24-6
Molecular Formula:
C21H25F3N6O2
Molecular Weight:
450.4574
MDL Number:
MFCD30470232
SMILES:
CCC(=O)N1CC[C@@H](C1)Nc1ncnc2c1CN(CC2)c1cnc(c(c1)C(F)(F)F)OC
Properties
Computed Properties
 
Complexity:
654  
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
1  
Heavy Atom Count:
32  
Hydrogen Bond Acceptor Count:
10  
Hydrogen Bond Donor Count:
1  
Rotatable Bond Count:
5  
XLogP3:
2.5  

Downstream Synthesis Route

[1]Patent:WO2012/4299,2012,A1.Locationinpatent:Page/Pagecolumn145

[2]ACSMedicinalChemistryLetters,2017,vol.8,p.975-980

[1]Patent:WO2012/4299,2012,A1.Locationinpatent:Page/Pagecolumn148-149

[2]Patent:WO2013/1445,2013,A1.Locationinpatent:Page/Pagecolumn62

[3]Patent:WO2013/88404,2013,A1.Locationinpatent:Page/Pagecolumn163

[4]Patent:US2015/342951,2015,A1.Locationinpatent:Paragraph0944

[1]Patent:WO2013/1445,2013,A1

[2]Patent:WO2013/88404,2013,A1

[3]Patent:US2015/342951,2015,A1

[4]Patent:WO2012/4299,2012,A1

[1]Patent:WO2013/1445,2013,A1

[2]Patent:WO2013/88404,2013,A1

[3]Patent:US2015/342951,2015,A1

[4]ACSMedicinalChemistryLetters,2017,vol.8,p.975-980

[5]Patent:WO2012/4299,2012,A1

[1]Patent:WO2012/4299,2012,A1.Locationinpatent:Page/Pagecolumn146-147

[2]Patent:US2015/342951,2015,A1.Locationinpatent:Paragraph0940

Literature

Title: Effective 'activated PI3Kδ syndrome'-targeted therapy with the PI3Kδ inhibitor leniolisib.

Journal: Blood 20171123

Title: Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors.

Journal: ACS medicinal chemistry letters 20170914

Title: Genetic defects in PI3Kδ affect B-cell differentiation and maturation leading to hypogammaglobulineamia and recurrent infections.

Journal: Clinical immunology (Orlando, Fla.) 20170301

Title: Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency.

Journal: Nature immunology 20140101

Title: Rao V, et al. Effective 'Activated PI3Kd Syndrome' -targeted therapy with PI3Kd inhibitor leniolisib. The New England journal of medicine: NEJM. ISSN 0028-4793; 1533-4406

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
Submit
SDS
Related Products of 1354690-24-6
1354691-97-6

1354691-97-6
Building Blocks
More >
Tags:1354690-24-6 Molecular Formula|1354690-24-6 MDL|1354690-24-6 SMILES|1354690-24-6 Leniolisib
Catalog No.: AA01EN2Q
1354690-24-6,MFCD30470232
1354690-24-6 | Leniolisib
Pack Size： 1mg
Purity： 98%
in stock
$19.00 $14.00
Pack Size： 5mg
Purity： 98%
in stock
$47.00 $33.00
Pack Size： 25mg
Purity： 98%
in stock
$119.00 $83.00
Quantity
- +
Add to Card
Order Now
bulk Quotation Request
Technical Information
Catalog Number: AA01EN2Q
Chemical Name: Leniolisib
CAS Number: 1354690-24-6
Molecular Formula: C21H25F3N6O2
Molecular Weight: 450.4574
MDL Number: MFCD30470232
SMILES: CCC(=O)N1CC[C@@H](C1)Nc1ncnc2c1CN(CC2)c1cnc(c(c1)C(F)(F)F)OC
Properties
Complexity: 654  
Covalently-Bonded Unit Count: 1  
Defined Atom Stereocenter Count: 1  
Heavy Atom Count: 32  
Hydrogen Bond Acceptor Count: 10  
Hydrogen Bond Donor Count: 1  
Rotatable Bond Count: 5  
XLogP3: 2.5  
Downstream Synthesis Route
1354692-00-4    79-03-8    1354690-24-6 

[1]Patent:WO2012/4299,2012,A1.Locationinpatent:Page/Pagecolumn145

[2]ACSMedicinalChemistryLetters,2017,vol.8,p.975-980

495-69-2    1354690-24-6    1354691-99-8 

[1]Patent:WO2012/4299,2012,A1.Locationinpatent:Page/Pagecolumn148-149

[2]Patent:WO2013/1445,2013,A1.Locationinpatent:Page/Pagecolumn62

[3]Patent:WO2013/88404,2013,A1.Locationinpatent:Page/Pagecolumn163

[4]Patent:US2015/342951,2015,A1.Locationinpatent:Paragraph0944

121643-44-5    1354690-24-6 

[1]Patent:WO2013/1445,2013,A1

[2]Patent:WO2013/88404,2013,A1

[3]Patent:US2015/342951,2015,A1

[4]Patent:WO2012/4299,2012,A1

914612-23-0    1354690-24-6 

[1]Patent:WO2013/1445,2013,A1

[2]Patent:WO2013/88404,2013,A1

[3]Patent:US2015/342951,2015,A1

[4]ACSMedicinalChemistryLetters,2017,vol.8,p.975-980

[5]Patent:WO2012/4299,2012,A1

1354690-24-6    1354691-97-6 

[1]Patent:WO2012/4299,2012,A1.Locationinpatent:Page/Pagecolumn146-147

[2]Patent:US2015/342951,2015,A1.Locationinpatent:Paragraph0940

Literature fold

Title: Effective 'activated PI3Kδ syndrome'-targeted therapy with the PI3Kδ inhibitor leniolisib.

Journal: Blood20171123

Title: Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors.

Journal: ACS medicinal chemistry letters20170914

Title: Genetic defects in PI3Kδ affect B-cell differentiation and maturation leading to hypogammaglobulineamia and recurrent infections.

Journal: Clinical immunology (Orlando, Fla.)20170301

Title: Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency.

Journal: Nature immunology20140101

Title: Rao V, et al. Effective 'Activated PI3Kd Syndrome' -targeted therapy with PI3Kd inhibitor leniolisib. The New England journal of medicine: NEJM. ISSN 0028-4793; 1533-4406

Related Products of of 1354690-24-6
1354691-97-6
1354691-97-6
Building Blocks More >
2088135-12-8
2088135-12-8
2-Chloro-N-(6-methoxy-4-quinolinyl)-5-nitrobenzamide
AA01ENFB | MFCD31656711
688347-51-5
688347-51-5
4-[[2-[[(2-Cyanophenyl)methyl]thio]-4-oxothieno[3,2-d]pyrimidin-3(4H)-yl]methyl]benzoicacid
AA01ENI8 | MFCD05032783
30195-30-3
30195-30-3
7-Chloro-1,3-dihydro-5-(1H-pyrrol-2-yl)-2H-1,4-benzodiazepin-2-one
AA01ENL4 | MFCD00870704
212609-11-5
212609-11-5
L-Glutamine,L-methionyl-L-prolyl-L-arginyl-L-valyl-L-arginyl-L-seryl-L-leucyl-L-phenylalanyl-L-glutaminyl-L-a-glutamyl-L-glutaminyl-L-a-glutamyl-L-a-glutamyl-L-prolyl-L-a-glutamyl-L-prolylglycyl-L-methionyl-L-a-glutamyl-L-a-glutamyl-L-alanylglycyl-L-a-glutamyl-L-methionyl-L-a-glutamyl-L-glutaminyl-L-lysyl-L-glutaminyl-L-leucyl-
AA01ENOL
1487360-85-9
1487360-85-9
Cyclosporin A-Derivative 1
AA01ENX2 | MFCD31619306
653592-04-2
653592-04-2
MT-DADMe-ImmA
AA01EO2D | MFCD30738019
1799506-06-1
1799506-06-1
HaloPROTAC 2
AA01EO66 | MFCD31692393
2070018-30-1
2070018-30-1
IDO-IN-3
AA01EOCV | MFCD29472227
135330-08-4
135330-08-4
RP-54745
AA01EOHL | MFCD00879121
1618658-88-0
1618658-88-0
CC-671
AA01EON9 | MFCD31619262
Submit
© 2017 AA BLOCKS, INC. All rights reserved.